Anti-VEGF targeting therapy in addition to chemotherapy increased the number of CD8+ T-cells in the peripheral blood in advanced melanoma patients [57] and improved antigen-specific CD8+ T-cell responses in vivo and in vitro in aNSCLC [40]. This evidence concerns the gene VEGFA and melanoma.